Crystal Structure of a p53 Tumor Suppressor-DNA Complex: Understanding Tumorigenic Mutations
The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
Mutations in the p53 tumor suppressor are the most frequently observed genetic alterations in human cancer. The majority of the mutations occur in the core domain which contains the sequence-specific DNA binding activity of the p53 protein (residues 102-292), and they result in loss of DNA binding. The crystal structure of a complex containing the core domain of human p53 and a DNA binding site has been determined at 2.2 angstroms resolution and refined to a crystallographic R factor of 20.5 percent. The core domain structure consists of a beta sandwich that serves as a scaffold for two large loops and a loop-sheet-helix motif. The two loops, which are held together in part by a tetrahedrally coordinated zinc atom, and the loop-sheet-helix motif form the DNA binding surface of p53. Residues from the loop-sheet-helix motif interact in the major groove of the DNA, while an arginine from one of the two large loops interacts in the minor groove. The loops and the loop-sheet-helix motif consist of the conserved regions of the core domain and contain the majority of the p53 mutations identified in tumors. The structure supports the hypothesis that DNA binding is critical for the biological activity of p53, and provides a framework for understanding how mutations inactivate it.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Modification of any of five arginine residues that are hotspots for TP53 mutations in human cancers disables TP53 sequence-specific DNA binding (Cho, et al., 1994).”
From The Mdm network and its regulation of p53 activities: a rheostat of cancer risk (2014) · cites this paper as Cho, et al., 1994
In the citing paper
“Gly-245 in the wild type adopts unusual backbone dihedral angles (1), which are not favored when the residue is replaced by serine.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The crystal structure of p53 core domain shows that the epitope of PAb240, located in strand 7, is inaccessible to antibody binding (1), and at least a partly unfolded form is required to expose the epitope.”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“The guanidinium group of Arg-249 is salt-bridged to the carboxylate group of Glu-171 in L2 and backbone oxygens of Gly-245 and Met-246 (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
In the citing paper
“suggesting the structure of p53 core domain in solution is similar to that in crystal structure (1).”
From Hot-spot mutants of p53 core domain evince characteristic local structural changes (1999) · cites this paper as [1]
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Kabsch, W., & Sander, C. (1983) · Biopolymers · doi:10.1002/bip.360221211 · Cited by 15,320
Jones, T. A., Zou, J. Y., Cowan, S. W., & Kjeldgaard, M. (1991) · Acta Crystallographica Section A Foundations of Crystallography · doi:10.1107/s0108767390010224 · Cited by 12,648
WAF1, a potential mediator of p53 tumor suppression
El-Deiry, W. S., Tokino, T., Velculescu, V. E., Levy, D. B., Parsons, R., Trent, J. M., Lin, D., Mercer, W. E., Kinzler, K. W., & Vogelstein, B. (1993) · Cell · doi:10.1016/0092-8674(93)90500-p · Cited by 8,321
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases.
Wade Harper, J. (1993) · Cell · doi:10.1016/0092-8674(93)90499-g · Cited by 5,651
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Principles of Nucleic Acid Structure
Saenger, W. (1984) · Springer Advanced Texts in Chemistry · doi:10.1007/978-1-4612-5190-3 · Cited by 4,150
The E6 oncoprotein encoded by human papillomavirus types 16 and 18 promotes the degradation of p53
Scheffner, M., Werness, B. A., Huibregtse, J. M., Levine, A. J., & Howley, P. M. (1990) · Cell · doi:10.1016/0092-8674(90)90409-8 · Cited by 3,995
The p53 tumour suppressor gene
Levine, A. J., Momand, J., & Finlay, C. A. (1991) · Nature · doi:10.1038/351453a0 · Cited by 3,788
Kastan, M. B., Zhan, Q., El-Deiry, W. S., Carrier, F., Jacks, T., Walsh, W. V., Plunkett, B. S., Vogelstein, B., & Fornace, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90593-2 · Cited by 3,047
Research works printed but not linked: 2
- SACK, J. S., JOURNAL OF MOLECULAR GRAPHICS 6: 224 (1988).
- TONRUD, D.E., ACTA CRYSTALLOGR A 43: 489 (1987).
Cited by
Items 1,301–1,400 of 2,517
Survival of patients with structurally-groupedTP53mutations in ovarian and breast cancers
Seagle, B.-L. L., Eng, K. H., Dandapani, M., Yeh, J. Y., Odunsi, K. O., & Shahabi, S. (2015) · Oncotarget · doi:10.18632/oncotarget.4080 · Cited by 26
“Initial KaplanMeier (KM) survival analysis included all structural groups defined by reference [10] as listed in Table 1.”
BackgroundMethodInfluentialVerkhivker, G. M. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.10.009 · Cited by 29
Anderson, C. W., & Appella, E. (2003) · Elsevier eBooks · doi:10.1016/b978-012124546-7/50668-9 · Cited by 36
Molecular margins in head and neck cancer: Current techniques and future directions
Stepan, K. O., Li, M. M., Kang, S. Y., & Puram, S. V. (2020) · Oral Oncology · doi:10.1016/j.oraloncology.2020.104893 · Cited by 32
Pan, C., Lin, F.-Y., Kao, L., Huang, C.-C., & Liu, P. (2020) · PLoS ONE · doi:10.1371/journal.pone.0232729 · Cited by 28
cDNA cloning and expression analysis of flounder p53 tumour suppressor gene
Cachot, J., Galgani, F., & Vincent-Hubert, F. (1998) · Comparative Biochemistry and Physiology Part B Biochemistry and Molecular Biology · doi:10.1016/s0305-0491(98)10133-5 · Cited by 25
Cai, B., Chen, J.-Y., Lu, M.-H., Chang, L.-T., Lin, H.-C., Chang, Y.-M., & Chao, C.-F. (2009) · Nucleic Acids Research · doi:10.1093/nar/gkp033 · Cited by 25
“p53 is composed of an N-terminal transactivation domain, a DNA-binding core domain and a C-terminal oligomerization domain (Figure 6A) (14).”
BackgroundCancer Progression Prediction Using Gene Interaction Regularized Elastic Net
Zhang, L., Liu, H., Huang, Y., Wang, X., Chen, Y., & Meng, J. (2015) · IEEE Transactions on Computational Biology and Bioinformatics · doi:10.1109/tcbb.2015.2511758 · Cited by 27
“Among the four genes, “TP53” is well known as a tumor suppressor that is involved in preventing cancer [45].”
BackgroundConstitutive DNase I Hypersensitivity of p53-Regulated Promoters
Braastad, C. D., Han, Z., & Hendrickson, E. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m204256200 · Cited by 27
Bipartite Tetracysteine Display Requires Site Flexibility for ReAsH Coordination
Goodman, J. L., Fried, D. B., & Schepartz, A. (2009) · ChemBioChem · doi:10.1002/cbic.200900207 · Cited by 26
In the Quest for Stable Rescuing Mutants of p53: Computational Mutagenesis of Flexible Loop L1
Pan, Y., Ma, B., Venkataraghavan, R. B., Levine, A. J., & Nussinov, R. (2005) · Biochemistry · doi:10.1021/bi047845y · Cited by 27
Cancer Predisposition in Mutant Mice Defective in the XPC DNA Repair Gene
Friedberg, E. C., Cheo, D. L., Meira, L. B., & dos Reis, A. M. (1999) · KARGER eBooks · doi:10.1159/000062011 · Cited by 30
Furihata, M., Kurabayashl, A., Matsumoto, M., Sonobe, H., Ohtsuki, Y., Terao, N., Kuwahara, M., & Shuin, T. (2002) · The Journal of Pathology · doi:10.1002/path.1082 · Cited by 26
Generation of Anti-p53 Fab Fragments from Individuals with Colorectal Cancer Using Phage Display
Coomber, D., Hawkins, N. J., Clark, M. A., & Ward, R. L. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.4.2276 · Cited by 26
“Point mutations in the central DNA binding domain are the most frequently observed mutation (2, 3), and result in loss of function due to conformational changes (4).”
Backgroundp53 and the CNS: Tumors and developmental abnormalities
Fulci, G., & Meir, E. G. V. (1999) · Molecular Neurobiology · doi:10.1007/bf02741378 · Cited by 29
“mutations decreases at increased distances from the biologically important structures of the gene product (16).”
Backgroundp53 Exon 7 mutations as a predictor of poor prognosis in patients with colorectal cancer
Iniesta, P., Vega, F. J. P., Caldés, T., et al. (1998) · Cancer Letters · doi:10.1016/s0304-3835(98)00138-4 · Cited by 26
“[33] to explain the molecular basis for p53 inactivation.”
BackgroundLi, B., Kittrell, F. S., Medina, D., & Rosen, J. M. (1995) · Molecular Carcinogenesis · doi:10.1002/mc.2940140203 · Cited by 25
The DNA Damage Checkpoint and Human Cancer
SCHULTZ, L. B., CHEHAB, N. H., MALIKZAY, A., DITULLIO, R. A., STAVRIDI, E. S., & HALAZONETIS, T. D. (2000) · Cold Spring Harbor Symposia on Quantitative Biology · doi:10.1101/sqb.2000.65.489 · Cited by 26
Germline mutation in the TP53 gene in uveal melanoma
Hájková, N., Hojny, J., Němejcová, K., Dundr, P., Ulrych, J., Jirsová, K., Glezgová, J., & Tichá, I. (2018) · Scientific Reports · doi:10.1038/s41598-018-26040-0 · Cited by 27
Saini, H., Hakeem, I., Mukherjee, S., Chowdhury, S., & Chowdhury, R. (2019) · Journal of Oncology · doi:10.1155/2019/6164807 · Cited by 25
Kim, J., Jeong, K., Jun, H., Kim, K., Bae, J. M., Song, M. G., Yi, H., Park, S., Woo, G.-U., Lee, D., et al. (2023) · Human Genomics · doi:10.1186/s40246-022-00447-3 · Cited by 28
“In our study, only one-third of the TP53 mutations were found in major grooves or zinc binding site of the DNAbinding domain [56].”
BackgroundChoe, J. H., Kawase, T., Xu, A., Guzman, A., Obradović, A., Low-Calle, A. M., Alaghebandan, B., Raghavan, A., Long, K., Hwang, P. M., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0882 · Cited by 25
Santi, R., Cetica, V., Franchi, A., et al. (2011) · Histopathology · doi:10.1111/j.1365-2559.2011.03770.x · Cited by 25
“Variations at this site make up 98% of the transforming mutations in p53.(19) Conversely, polymorphic sequence variations are expected to have modest or no cancer-related biological effect.”
BackgroundAdduri, S., Kotapalli, V., Gupta, N. A., Gowrishankar, S., Srinivasulu, M., Ali, M. M., Rao, S., Uppin, S. G., Nayak, U. K., Dhagam, S., et al. (2014) · BMC Clinical Pathology · doi:10.1186/1472-6890-14-37 · Cited by 28
“The deleted amino acids include four (143–146) that form part of β-sheet S3 which is important in stabilizing the loop- β sheet- α helix motif, a key domain in formation of p53 DNA binding surface [10].”
BackgroundTranscriptional regulation of the legumain gene by p53 in HCT116 cells
Yamane, T., Murao, S., Kato-Ose, I., Kashima, L., Yuguchi, M., Kozuka, M., Takeuchi, K., Ogita, H., Ohkubo, I., & Ariga, H. (2013) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2013.08.007 · Cited by 25
“p53 tumor suppressor is a well-known transcription factor that modulates the expression of numerous genes involved in various cellular functions, including anti-angiogenesis, cell cycle arrest and induction of apoptosis [16,17].”
BackgroundPatel, S. V., Bui, T. T. T., Drake, A. F., Fraternali, F., & Nikolova, P. V. (2008) · Biochemistry · doi:10.1021/bi7023207 · Cited by 27
“In solution, the core DNA binding domains of the p53 family of proteins would seem to contain mostly -sheet structure, which is expected from the known crystal structure of p53 DBD (4).”
BackgroundMutational analysis of tumor suppressor gene p53 in feline vaccine site-associated sarcomas
Nambiar, P. R., Haines, D. M., Ellis, J. A., et al. (2000) · American Journal of Veterinary Research · doi:10.2460/ajvr.2000.61.1277 · Cited by 25
Fimognari, C., Lenzi, M., Sciuscio, D., et al. (2007) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1397.008 · Cited by 25
Ethayathulla, A. S., Nguyen, H. T., & Viadiu, H. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m112.408039 · Cited by 24
Hu, X., Chen, H., Jin, M., et al. (2012) · Molecular Cytogenetics · doi:10.1186/1755-8166-5-26 · Cited by 25
“Interestingly, all these mutations, identified in cases with UESL, namely, K120M [11], V216M [11], S245G [10], and R248W (our case) are located in the sequence-specific DNA binding domain (amino acid residues 102–292 out of the 393 of the p53 protein), where the hot spots of mutations are located [17].”
BackgroundBehind the scenes: Unravelling the molecular mechanisms of p53 target gene selectivity (Review)
Lohrum (2010) · International Journal of Oncology · doi:10.3892/ijo_00000757 · Cited by 30
“This domain has been defined by numerous biochemical studies and its interaction with DNA has been visualized by X-ray crystallography, which supported the hypothesis that DNA binding is critical for the biological activity of p53 (79-81).”
BackgroundGrochová, D., Vaňková, J., Damborský, J., Ravčuková, B., Šmarda, J., Vojtěšek, B., & Šmardová, J. (2007) · Oncogene · doi:10.1038/sj.onc.1210748 · Cited by 29
“…lymphoid leukemia; DLBCL, diffuse large B-cell lymphoma; HNSCC, head and neck squamous cell carcinoma; MCL, mantle cell lymphoma; MDS, myelodysplastic syndrome; MM, malignant melanoma. aAccording to IARC database R11 (http://www.iarc.fr/p53; Olivier et al., 2002). bAccording to Cho et al. (1994).”
BackgroundMethodRíos, R., Lupiañez, C. B., Campa, D., Hielscher, T., Weinhold, N., Martínez‐López, J., Jerez, A., Landi, S., Jamroziak, K., Dumontet, C., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10665 · Cited by 25
Platelet-rich plasma ameliorates senescence-like phenotypes in a cellular photoaging model
Jia, C., Lu, Y., Bi, B., Chen, L., Yang, Q., Yang, P. C., Guo, Y., Zhu, J., Zhu, N., & Liu, T. (2017) · RSC Advances · doi:10.1039/c6ra26725d · Cited by 26
Signorelli, S., Santini, S., Yamada, T., Bizzarri, A. R., Beattie, C. W., & Cannistraro, S. (2017) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2017.01.022 · Cited by 25
Giel-Pietraszuk, M., Hoffmann, M., Dolecka, S., Rychlewski, J., & Barciszewski, J. (2003) · Journal of Protein Chemistry · doi:10.1023/a:1023454111924 · Cited by 26
p73 can suppress the proliferation of cells that express mutant p53
Willis, A. C., Pipes, T., Zhu, J., & Chen, X. (2003) · Oncogene · doi:10.1038/sj.onc.1206505 · Cited by 30
“The conformational mutants, for example, V143A, R249S, and R175H, alter the structure of the protein (Cho et al., 1994), while the contact site mutants, for example, R248W and R273H, have an altered residue at a site that, in the wild-type protein, directly contacts DNA (Cho et al., 1994; Rolley et…”
Backgroundp53 mutation as a potential cellular factor for tumor development in enzootic bovine leukosis
Ishiguro, N., Furuoka, H., MATSUI, T., Horiuchi, M., Shinagawa, M., Asahina, M., & Okada, K. (1997) · Veterinary Immunology and Immunopathology · doi:10.1016/s0165-2427(96)05721-2 · Cited by 26
Ryk, C., Berggren, P., Kumar, R., Hemminki, K., Larsson, P., Steineck, G., Lambert, B., & Hou, S. (2004) · International Journal of Cancer · doi:10.1002/ijc.20650 · Cited by 28
Conservation of metal‐coordinating residues
Kasampalidis, I. N., Pitas, I., & Lyroudia, K. (2007) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.21384 · Cited by 24
“Zinc is a crucial metal, used, among others, to stabilize DNAbinding domains in a number of transcription factors, p53 being a most important example.(23) Another main family of proteins utilizing zinc is the zinc-finger family, which includes several hundreds of members, including Krox-26, a transcription factor, whi…”
Retzlaff, M., Rohrberg, J., Küpper, N. J., Lagleder, S., Bepperling, A., Manzenrieder, F., Peschek, J., Kessler, H., & Büchner, J. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.10.015 · Cited by 35
DNA Repair Enhancement by a Combined Supplement of Carotenoids, Nicotinamide, and Zinc
Sheng, Y., Pero, R. W., Olsson, A. R., Bryngelsson, C., & Hua, J. (1998) · Cancer Detection and Prevention · doi:10.1046/j.1525-1500.1998.cdoa37.x · Cited by 26
Zhang, H., Yang, X., Wang, K., Tan, W., Li, H., Zuo, X., & Wen, J. (2007) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2007.09.012 · Cited by 25
JAK2V617F and p53 mutations coexist in erythroleukemia and megakaryoblastic leukemic cell lines
Zhao, W., Du, Y., Ho, W., Fu, X., & Zhao, Z. J. (2012) · Experimental Hematology and Oncology · doi:10.1186/2162-3619-1-15 · Cited by 25
“Based on the crystal structure of the DNA binding domain of p53 in complex with DNA [15], structure analyses predict that both mutations have deleterious effects on p53 function (Figure 4).”
BackgroundSimão, T. D. A., Ribeiro, F. S., de Amorim, L. M. D. F., et al. (2002) · International Journal of Cancer · doi:10.1002/ijc.10567 · Cited by 25
Molecular Evolution of the Thermosensitive PAb1620 Epitope of Human p53 by DNA Shuffling
Xirodimas, D. P., & Lane, D. P. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.39.28042 · Cited by 28
Wolkowicz, R., Peled, A., Elkind, N. B., et al. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.15.6842 · Cited by 25
Takahashi, Y., Ishii, Y., Nagata, T., et al. (2002) · Oncology · doi:10.1159/000066510 · Cited by 25
p53 biology and reactivation for improved therapy in MDS and AML
Zawacka‐Pankau, J. (2024) · Biomarker Research · doi:10.1186/s40364-024-00579-9 · Cited by 28
“Contact mutants like p53-R273H or p53-R248Q display aberrant interactions with DNA as reported by several labs [59, 60], yet, unlike conformational mutants (e.g. p53-R175H), have a structure similar to wild-type protein [61].”
BackgroundTherapeutic Strategies to Activate p53
Aguilar, A., & Wang, S. (2022) · Pharmaceuticals · doi:10.3390/ph16010024 · Cited by 34
Analysing the ability to retain sidechain hydrogen-bonds in mutant proteins
Cuff, A. L., Janes, R. W., & Martin, A. C. R. (2006) · Bioinformatics · doi:10.1093/bioinformatics/btl120 · Cited by 24
“The program was applied to the assessment of mutations in the core domain of the tumour-suppressor protein, p53 (Cho et al., 1994, PDB file: Itsr). p53 is mutated in >50% of human cancers and in a recent study by Martin et al. (2002), an automated protocol was developed to classify the effects of…”
MethodPreuss, U., Kreutzfeld, R., & Scheidtmann, K.-H. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001015)88:2<162::aid-ijc3>3.0.co;2-m · Cited by 24
Mutation at p53 serine 389 does not rescue the embryonic lethality in mdm2 or mdm4 null mice
Iwakuma, T., Parant, J. M., Fasulo, M., Zwart, E., Jacks, T., de Vries, A., & Lozano, G. (2004) · Oncogene · doi:10.1038/sj.onc.1207793 · Cited by 27
“This region is a hot spot for mutations in human tumors, leading to an inactivation of p53 transcriptional activity (Cho et al., 1994).”
BackgroundThe Continuing Saga of p53— More Sleepless Nights Ahead
Prives, C. L., & Manfredi, J. J. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.08.024 · Cited by 25
Mathé, E. A., Olivier, M., Kato, S., Ishioka, C., Vaisman, I. I., & Hainaut, P. L. (2006) · Human Mutation · doi:10.1002/humu.20284 · Cited by 26
“All potential score calculations were based on the X-ray structure of the DBD of p53 (PDB [Berman et al., 2000] ID 1tsr, chain B), which includes 194 amino acids (residues 96–289) [Cho et al., 1994].”
MethodKaiser, M. W., & Brow, D. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.19.11398 · Cited by 23
Zaffaroni, N., Benini, E., Gornati, D., Bearzatto, A., & Silvestrini, R. (1995) · Stem Cells · doi:10.1002/stem.5530130110 · Cited by 23
Wu, Y., Huang, H., Miner, Z., & Kulesz-Martin, M. F. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.17.8982 · Cited by 23
Hormonal regulation of tumor suppressor proteins in breast cancer cells
Moudgil, V. K., Dinda, S., Khattree, N., Jhanwar, S. C., Alban, P., & Hurd, C. (2001) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(00)00151-5 · Cited by 24
Picksley, S. M., Spicer, J. F., Barnes, D. M., & Lane, D. P. (1996) · Acta Oncologica · doi:10.3109/02841869609109917 · Cited by 26
Bizzarri, A. R., Moscetti, I., & Cannistraro, S. (2018) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2018.11.003 · Cited by 23
Redox Sensitive Cysteine Residues as Crucial Regulators of Wild-Type and Mutant p53 Isoforms
Butturini, E., Butera, G., Pacchiana, R., de Prati, A. C., Mariotto, S., & Donadelli, M. (2021) · Cells · doi:10.3390/cells10113149 · Cited by 28
“229) [61] and three of which are involved in the coordination of zinc ions (Cys 176, 238, and 242, along with His 179) [62] and are important to maintain the p53 structure.”
BackgroundInfluentialp53 alters intracellular Ca2+ signaling through regulation of TRPM4
Kappel, S., Ross‐Kaschitza, D., Hauert, B., Rother, K., & Peinelt, C. (2022) · Cell Calcium · doi:10.1016/j.ceca.2022.102591 · Cited by 25
The Apelin/APLNR system modulates tumor immune response by reshaping the tumor microenvironment
Yang, Y., Chen, M., Qiu, Y., Li, X., Huang, Y., & Zhang, W. (2022) · Gene · doi:10.1016/j.gene.2022.146564 · Cited by 23
P63 and P73 Activation in Cancers with p53 Mutation
Cai, B., Hsu, Y.-C., Yeh, F.-Y., Lin, Y.-R., Lu, R.-Y., Yu, S.-J., Shaw, J., Wu, M.-H., Tsai, Y.-Z., Lin, Y.-C., et al. (2022) · Biomedicines · doi:10.3390/biomedicines10071490 · Cited by 30
Anticancer Therapeutic Strategies Targeting p53 Aggregation
Ferretti, G. D. S., Quarti, J., dos Santos, G., Rangel, L. P., & Silva, J. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms231911023 · Cited by 24
Structure and Stability Insights into Tumour Suppressor p53 Evolutionary Related Proteins
Pagano, B., Jama, A., Martinez, P., Akanho, E., Bui, T. T. T., Drake, A. F., Fraternali, F., & Nikolova, P. V. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076014 · Cited by 24
“It is known that the Homo sapiens p53 protein [18-22] consists of a central DNA-Binding domain (DBD), a tetramerization domain (TD), a trans-activation domain (TA) as well as a C-terminal regulatory domain.”
BackgroundMalčíková, J., Tichý, B., Damborský, J., Kabáthová, J., Trbušek, M., Mayer, J., & Pospíšilová, Š. (2010) · Biological Chemistry · doi:10.1515/bc.2010.027 · Cited by 23
“Structure-function relationships were studied with the structure of the p53 DNA-binding domain (Cho et al., 1994) and solved by crystallographic analysis (PDB ID 1TSR) using the visualization software PyMOL v0.”
MethodAminothiol WR1065 induces differential gene expression in the presence of wild-type p53
Mann, K., & Hainaut, P. L. (2005) · Oncogene · doi:10.1038/sj.onc.1208563 · Cited by 24
“The p53 protein contains a structural ‘redox sensor’ in the form of several critical cysteine residues located in the DNA-binding surface of the protein, three of which are involved in the coordination of a zinc atom (Cho et al, 1994; Rainwater et al., 1995).”
BackgroundMechanism of DNA-binding loss upon single-point mutation in p53
Wright, J. D., & Lim, C. (2007) · Journal of Biosciences · doi:10.1007/s12038-007-0083-3 · Cited by 23
“32(5), August 2007 data (Cho et al 1994), failure of p53 contact mutants, which retain the wild–type p53c conformation (Ory et al 1994), to act as a sequence–specifi c transactivator has been attributed to loss of critical DNA contacts, while failure of p53 conformational mutants to bind DNA in a…”
BackgroundMethodInfluentialMurata, H., Sakaguchi, M., Futami, J., Kitazoe, M., Maeda, T., Doura, H., Kosaka, M., Tada, H., Seno, M., Huh, N.-H., et al. (2006) · Biochemistry · doi:10.1021/bi052642a · Cited by 31
Genetic variants and protein–protein interactions: a multidimensional network-centric view
Laddach, A., Ng, J. C.-F., Chung, S. S., & Fraternali, F. (2018) · Current Opinion in Structural Biology · doi:10.1016/j.sbi.2017.12.006 · Cited by 25
Huang, F., Wong, D. K.-H., Tsui, V. W. M., Seto, W., Mak, L., Cheung, T. T., Lai, K. K. Y., & Yuen, M.-F. (2019) · BMC Cancer · doi:10.1186/s12885-019-6002-9 · Cited by 25
Brattström, D., Bergqvist, M., Lamberg, K., et al. (1998) · Medical Oncology · doi:10.1007/bf02787209 · Cited by 23
Recognition of DNA modified by antitumor cisplatin by “latent” and “active” protein p53
Fojta, M., Pivoňková, H., Brázdová, M., Kovářová, L., Paleček, E., Pospíšilová, Š., Vojtěšek, B., Kašpárková, J., & Brabec, V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00078-9 · Cited by 23
Target gene modulation in hepatocellular carcinomas by decreased DNA-binding of p53 mutations
Kubicka, S., Trautwein, C., Niehof, M., et al. (1997) · Hepatology · doi:10.1002/hep.510250414 · Cited by 23
Bazan, V., Migliavacca, M., Tubiolo, C., et al. (2002) · Journal of Cellular Physiology · doi:10.1002/jcp.10088 · Cited by 23
Effect of p53 Polymorphism on the Susceptibility of Cervical Cancer
Yang, Y., Chang, C.-L., & Chen, M.-L. (2001) · Gynecologic and Obstetric Investigation · doi:10.1159/000052924 · Cited by 23
Kašpárková, J. (2004) · Nucleic Acids Research · doi:10.1093/nar/gkh896 · Cited by 23
“It is reasonable to expect that this location of the linker could sterically block the binding of the p53 protein to DNA [since the protein residues are also localized in DNA minor groove (40)].”
BackgroundRegulation of Thyroid Follicular Cell Function by Intracellular Redox-Active Copper
Iseki, A., Kambe, F., Okumura, K., Hayakawa, T., & Seo, H. (2000) · Endocrinology · doi:10.1210/endo.141.12.7835 · Cited by 23
Gorgoulis, V. G., Zacharatos, P., Manolis, E. N., Ikonomopoulos, J., Damalas, A., Lamprinopoulos, C., Rassidakis, G. Z., Zoumpourlis, V. C., Kotsinas, A., Rassidakis, A., et al. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.60 · Cited by 23
Brandt‐Rauf, P. W., Chen, J., Marion, M., et al. (1996) · Journal of Protein Chemistry · doi:10.1007/bf01886863 · Cited by 23
When viral oncoprotein meets tumor suppressor: a structural view
Liu, X., & Marmorstein, R. (2006) · Genes & Development · doi:10.1101/gad.1471706 · Cited by 24
“…magnetic resonance (NMR), and other biophysical studies, generating a plethora of information and hypotheses on the mode of DNA binding and p53 oligomerization for the regulation of various p53 functions (Cho et al. 1994; Lee et al. 1994; Jeffrey et al. 1995; Zhao et al. 2001; Ho et al. 2006).”
BackgroundTP53 mutations in primary breast carcinomas from white and African-Brazilian patients
Nagai, M. A., Barbosa, H. S., Zago, M. A., Silva, W. A., Nishimoto, I. N., Salaorni, S., Costa, L. G., Araújo, M. S., Oliveira, A. G. C., Neto, M. M., et al. (2003) · International Journal of Oncology · doi:10.3892/ijo.23.1.189 · Cited by 23
“However, the nature, type and site of these mutations vary among different tumor types and depend on different carcinogen exposure (5).”
Moxley, A. H., & Reisman, D. (2020) · Cell Biochemistry and Function · doi:10.1002/cbf.3590 · Cited by 27
“the DBD, one quarter of all mutations occur within the same six “hotspots”: R175, G245, R248, R249, R273, and R282.(5,98,102,103) F IGURE 3 p53 is expressed in 12 unique isoforms.”
BackgroundZhang, H., Zhang, W., Hu, B., Qin, X., Yi, T., Ye, Y., Huang, X., Song, Y., Yang, Z., Qian, J., et al. (2023) · Journal of Nanobiotechnology · doi:10.1186/s12951-023-01867-6 · Cited by 24
“In contrast to the wild-type p53 protein, the mutp53, in most cases, loses the ability to interact with the specific DNA-binding sequence and consequently cannot activate the p53 tumor suppressive transcription response due to loss of wild-type p53 activity [7, 8].”
BackgroundStructural Basis for ASPP2 Recognition by the Tumor Suppressor p73
Canning, P., von Delft, F., & Bullock, A. N. (2012) · Journal of Molecular Biology · doi:10.1016/j.jmb.2012.08.005 · Cited by 22
“1).(27) The DNA-binding surface is constructed similarly from the large L2 and L3 loops, the S10 β-strand and a loop–sheet–helix motif that includes the L1 loop, the S2 and S2′ β-strands and the C-terminal H2 α-helix.”
BackgroundCooperativity Dominates the Genomic Organization of p53-Response Elements: A Mechanistic View
Pan, Y., & Nussinov, R. (2009) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1000448 · Cited by 22
“Modeling of p53 dimer-dimer interfaces for complexes with base pair insertions The p53 core domain dimer-half site DNA complex generated previously [17] using the crystal structure of Cho et al [14] was used for the construction of all complexes with bp insertions.”
BackgroundMethodConstitutive and induced functions of the p53 gene
Zheltukhin, A. O., & Chumakov, P. M. (2010) · Biochemistry (Moscow) · doi:10.1134/s0006297910130110 · Cited by 33
Calcium, Vitamin D, VDR Genotypes, and Epigenetic and Genetic Changes in Rectal Tumors
Slattery, M. L., Wolff, R. K., Herrick, J. S., et al. (2010) · Nutrition and Cancer · doi:10.1080/01635580903441204 · Cited by 22
“Furthermore, specific point mutations such as an arginine residue at codon 248 in the L3 loop of the core domain of the gene is thought to play a critical role in DNA binding; a glycine at codon 245 also in the L3 loop allows the L3 loop to assume unique conformations; arginine at codon 273 in the loop-sheethelix moti…”
BackgroundMolecular Markers with Predictive and Prognostic Relevance in Lung Cancer
Rose-James, A., & Sreelekha, T. T. (2012) · Lung Cancer International · doi:10.1155/2012/729532 · Cited by 27
“The rate of P53 mutations in NSCLC varies from 30% to 50% of the cases and is clustered at codons 157, 158, 248, 249, 273, and 282 within exons 5 and 8 [28–30].”
BackgroundLiang, M., Han, X., Vadhan‐Raj, S., Nguyen, M. H., Zhang, Y. H., Fernandez, M., Drakos, E., Konoplev, S. N., Yin, C. C., Miranda, R. N., et al. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.170 · Cited by 27
“24 It is located in the Loop-L1 of the central core domain, which contains the sequence-specific DNA-binding activity of the p53 protein (residues 102–292)”
BackgroundTP63 Gene Mutations in Chinese P63 Syndrome Patients
Yin, W., Ye, X., Shi, L., Wang, Q. K., Jin, H., Wang, P., & Bian, Z. (2010) · Journal of Dental Research · doi:10.1177/0022034510366804 · Cited by 24
“Modeling of the TP63 protein 3D structure was based on its homologue, p53, for which the crystal structure has been solved (Cho et al., 1994).”
BackgroundUsing peptides to study the interaction between the p53 tetramerization domain and HIV‐1 tat
Gabizon, R., Mor, M., Rosenberg, M. M., Britan, L., Hayouka, Z., Kotler, M., Shalev, D. E., & Friedler, A. (2008) · Biopolymers · doi:10.1002/bip.20919 · Cited by 24
Munch-Petersen, H. R., Asmar, F., Dimopoulos, K., Areškevičiūtė, A., Brown, P. D. N., Girkov, M. S., Pedersen, A., Sjø, L. D., Heegaard, S., Broholm, H., et al. (2016) · Acta Neuropathologica Communications · doi:10.1186/s40478-016-0307-6 · Cited by 22
“Indeed, the majority of cancer-related TP53 mutations occur in the region of the DBD, which contains the Loop (L1)-sheet-helix (LSH) motif, two large loops L2 and L3, the direct DNA contact areas including the zinc-binding site, and the hotspots [5, 9, 51, 52].”
BackgroundOlotu, F. A., & Soliman, M. E. S. (2018) · Journal of Cellular Biochemistry · doi:10.1002/jcb.27458 · Cited by 23
“Contact mutations involve the substitution of DNA contact amino acid residues (R248 and R273) while structural mutations (R175, G245, R282, and R249) perturb the overall protein structure by substitution of amino acid residues essential for maintaining the structural integrity of the core domain.(7,14) The highlight o…”
BackgroundInfluentialMoscetti, I., Cannistraro, S., & Bizzarri, A. R. (2019) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2019.05.026 · Cited by 22
Mutant p53 as an Antigen in Cancer Immunotherapy
Sobhani, N., D’Angelo, A., Wang, X., Young, K. H., Generali, D., & Li, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21114087 · Cited by 25
“The protein has a central region made of 102–292 amino acids [98].”
BackgroundIntroduction to protein folding for physicists
Echenique, P. (2007) · Contemporary Physics · doi:10.1080/00107510701520843 · Cited by 41
“the tumor suppressor p53 protein [2].”
Involvement of reactive oxygen species and caspase 3 activation in arsenite-induced apoptosis
Chen, Y.-C., Lin-Shiau, S.-Y., & Lin, J.-K. (1998) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(199811)177:2<324::aid-jcp14>3.0.co;2-9 · Cited by 465
Metadata
- Authors
- Cho, Y., Gorina, S., Jeffrey, P. D., & Pavletich, N. P.
- Affiliations
- Memorial Sloan Kettering Cancer Center (US)
- Venue
- Science
- Published
- 1994-07-15
- Volume
- 265
- Issue
- 5170
- Pages
- 346-355
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2096276671
- Semantic Scholar
- 11096f3b08e172ce5e261795b6749818ee59c03d
- Cited by
- 2,551
- References
- 62
- Citations by year
- 2026: 62 · 2025: 52 · 2024: 40 · 2023: 64 · 2022: 61 · 2021: 73 · 2020: 67 · 2019: 62 · 2018: 61 · 2017: 54 · 2016: 64 · 2015: 62 · 2014: 81 · 2013: 78 · 2012: 68
- FWCI
- 64.38
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Open Access System for Information Sharing (Pohang University of Science and Technology) (submittedVersion)
- Funders
- National Cancer Institute (NCI CA08748-29)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Structure and Dynamics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Structural Biology › Enzyme Structure and Function
- Keywords
- p53 tumor suppressor, p53 core domain, DNA binding, zinc coordination, beta-sandwich, cancer genetics
- MeSH terms
- Amino Acid Sequence, Base Sequence, Binding Sites, Computer Graphics, Crystallization, DNA, Hydrogen Bonding, Models, Molecular, Molecular Sequence Data, Mutation, Nucleic Acid Conformation, Protein Conformation, Genes, p53, Tumor Suppressor Protein p53, Protein Structure, Secondary, Crystallography, X-Ray
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.